Indocollyre (Indometacin eye drops) is generally applied across domains where additional symptomatic support is needed, and is considered relevant in ophthalmological contexts. It is relevant in contexts marked by increased discomfort related to inflammatory or irritative states, where symptoms may create noticeable physiological strain or discomfort.

This medication is commonly used to help with symptomatic relief from the acute physical discomfort, pain, redness, and swelling that frequently arise following common procedures like cataract removal.

“It is applied in clinical settings that involve acute or disruptive symptom patterns, and contributes to improved day-to-day comfort during symptomatic periods.”

Easing Symptom Burden in Acute Ocular Contexts

Indocollyre is commonly used to address symptom clusters that may become intense or disruptive, such as inflammation and pain after eye surgery or in cases of specific non-infectious ocular inflammation. It contributes to easing the overall symptom load when symptoms interfere with daily comfort. It is often used when symptoms intensify and supportive relief is needed.

Quick Fact: Relief for Acute Ocular Pain and Swelling

Regulatory References

1. Health Canada Prescribing Information for Indomethacin Ophthalmic Suspension

Eligibility for Indocollyre (Indometacin) Eye Drops

The eligibility for using Indocollyre is strictly defined by regulatory documents, focusing on patient history and physiological status.

Absolute Contraindications (Must Not Use):

Conditional Use and Restrictions:

• Pediatric Use: Use is not recommended in children under 12 years of age because the safety and effectiveness have not been formally established.
• Breastfeeding: Use is not recommended for nursing mothers, as the medicine may pass into breast milk.
• Mid-Pregnancy (20–30 weeks): Use is restricted and only permitted if necessary, for the shortest possible duration.
• Specific Conditions: Use requires caution in patients with conditions such as corneal epithelial damage, bleeding disorders, rheumatoid arthritis, or diabetes, due to the potential for complications related to the drug class.

Interactions with other medicines and products

Indocollyre is an ophthalmic preparation containing Indometacin, a Non-Steroidal Anti-Inflammatory Drug (NSAID). Due to its topical route of administration, systemic exposure is low, minimizing the risk of most documented drug-drug interactions. However, official regulatory information maintains cautions based on the active ingredient’s known effects.

Pharmacodynamic Interaction Risks

Co-administration with medicines that interfere with blood clotting, such as anticoagulants (e.g., Warfarin) and certain antidepressants (SSRIs/SNRIs), is associated with a regulatory caution for an increased risk of bleeding. Furthermore, Indometacin may diminish the blood pressure-lowering effect of Antihypertensive Agents (e.g., ACE Inhibitors, ARBs) and reduce the effect of Diuretics. The interaction with ACE Inhibitors or ARBs carries a specific note for elderly or volume-depleted patients regarding a heightened risk of renal function deterioration.

Exposure and Timing Restrictions

Indometacin is documented to alter the plasma levels of certain medicines by reducing their clearance, leading to an increased serum concentration of drugs like Digoxin and Lithium. A specific timing-separation rule is necessary for co-administration with other eye drops (e.g., Ciprofloxacin) to avoid physical/chemical incompatibility that can cause precipitation on the eye surface. The active substance, Indometacin, also has a documented substance interaction with alcohol, which can increase the risk of serious gastrointestinal events.

Direct Inhibition of the Prostaglandin Synthesis Pathway

Indometacin functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzyme, blocking both the COX-1 and COX-2 isoforms within the eye. This core molecular action suppresses the biosynthesis of Prostaglandins, which are key chemical mediators that facilitate the inflammatory response. The mechanism also involves secondary inhibition of the precursor enzyme Phospholipase A2 and stabilization of lysosomal membranes, which collectively reduces the overall chemical output of the inflammatory cascade.

Modulation of Vascular Dynamics and Nociceptor Sensitization Pathways

The suppression of Prostaglandin production leads to the cessation of their signaling role as pathological vasodilators and permeabilizers. This limits pathological vasodilation and increased fluid extravasation (leakage) in the ocular tissue. Furthermore, this mechanism contributes to the desensitization of nociceptors, thereby reducing the intensity of afferent sensory signaling originating from the site of inflammation.

Interfering with Trauma-Induced Pupil Constriction

A specialized action of the mechanism is the stabilization of iris smooth muscle tone by interfering with prostaglandin-induced constriction (miosis) that is chemically triggered by mechanical trauma. By proactively blocking the surge of prostaglandins that normally signals the iris sphincter muscle to contract, the drug maintains the muscle tone by interfering with the chemical signal for constriction in the anterior part of the eye.

Administration of Indocollyre

Indocollyre is an ophthalmic solution containing indometacin, a non-steroidal anti-inflammatory drug (NSAID). It is designed specifically for topical application to the eye. Proper administration technique is essential to ensure the solution is applied effectively and to minimize the risk of contamination.

Application Technique

To apply the eye drops, the head should be tilted back slightly while looking upward. By gently pulling down the lower eyelid, a small pocket is created. The dropper tip is held above the eye without making direct contact with the eye, eyelids, or any surrounding surfaces. The prescribed number of drops is then released into the conjunctival sac.

After application, closing the eye gently for one to two minutes can help the medication distribute across the surface. Applying light pressure to the inner corner of the eye (near the nose) for approximately one minute may reduce systemic absorption of the medication through the tear ducts.

Hygiene and Care

Maintaining the sterility of the solution is a priority. Hands should be washed thoroughly with soap and water before and after handling the bottle. The cap should be replaced immediately after use, and the dropper tip must not touch any surface, including the eye itself, to prevent bacterial contamination of the remaining solution.

Use with Other Ophthalmic Products

If other eye drops or ointments are being used concurrently, a specific sequence and interval are typically required. Generally, different eye medications should be administered at least five to ten minutes apart to prevent the first medication from being washed out by the second. If both drops and ointments are prescribed, the drops are usually applied first, followed by the ointment.

Contact Lens Considerations

Indocollyre often contains preservatives that may be absorbed by soft contact lenses. It is standard practice to remove contact lenses before applying the drops. Lenses can usually be reinserted after a short waiting period following administration.

Research evidence / Overview of studies for Indocollyre (Indometacin)

Evidence for Use in Managing Inflammation After Cataract Surgery

Research for this use was primarily conducted through Randomized Controlled Trials (RCTs) and systematic reviews and meta-analyses that combine data from multiple clinical settings. These studies examined outcomes related to inflammatory or irritative states in the eye, such as the amount of cell infiltration and flare in the anterior chamber, and patient-reported outcomes describing perceived discomfort, such as postsurgical pain. Researchers mainly examined adult populations immediately following routine cataract removal procedures.

In these research contexts, studies monitored the measured values of objective inflammation markers and subjective pain ratings. Findings describe patterns observed in the studies regarding how cell and flare scores evolved during the short-term observation period immediately following surgery.

Evidence for Preventing Macular Edema Following Eye Surgery

This body of research includes prospective studies and systematic reviews, which was observed in studies examining delayed postsurgical complications. Researchers primarily explored the incidence and objective measurement of fluid accumulation in the retina (Macular Edema or CME). Outcomes related to this condition include objective changes quantified by specialized imaging tools.

Reports derived from this research data show patterns related to the observed rate of fluid accumulation when compared against control or placebo groups over several months. Research provides insight into short-term changes in the rate of this specific postsurgical complication.

Long-Term Studies and Follow-Up Observation Periods

Most published research for Indocollyre (Indometacin) was observed in defined time intervals, typically focused on the acute postsurgical phase, which generally extends up to three months. The evidence describing the patterns observed beyond this short-to-intermediate timeframe is limited. Limited information for long-term outcomes is available.

What is Still Uncertain About Indocollyre (Indometacin) Research

Research has been conducted on the specific conditions studied, but data for certain groups remains limited. This includes populations such as children, pregnant or lactating individuals, and patients with certain pre-existing systemic conditions. Subgroup findings are uncertain for many of these specific patient contexts. Furthermore, comparative evidence is lacking in some areas, meaning direct head-to-head research against all possible alternative treatments is not consistently available across the literature.

Key Studies & References

1. [Anti-inflammatory effects and aqueous humor concentration of various nonsteroidal anti-inflammatory drugs in extracapsular cataract surgery]
2. Update in treatment of uveitic macular edema
3. Indocollyre 0.1 % eye drops solution dropper container (Product Information)
4. Indomethacin Suppositories - Product Monograph (Health Canada/Regulatory Document providing context on special populations)

Common questions about Indocollyre (Indometacin) (FAQ)

Q: What is the role of Indocollyre eye drops in ophthalmology?

A: Indocollyre is an anti-inflammatory medicine available as eye drops. According to the regulatory documents, its main role is to help manage inflammation (such as pain, swelling, or redness) that is not caused by an infection. This application is typically related to specific eye procedures or existing non-infectious conditions.

Q: Does Indocollyre contain preservatives?

A: Yes, regulatory information confirms that Indocollyre eye drops contain benzalkonium chloride as a preservative. The official product information notes that the presence of benzalkonium chloride is relevant for users of soft contact lenses, as it may cause discoloration.

Q: Is Indocollyre an antibiotic or an anti-inflammatory drug?

A: Indocollyre contains indometacin, which belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Official product information confirms that its primary action is to reduce inflammation and pain. It is not classified as an antibiotic, and therefore does not fight bacterial infections.

Q: Can I use Indocollyre if I have a history of allergies to anti-inflammatory medicines?

A: Official product information states that the medicine is contraindicated (should not be used) if a person is known to be allergic to indometacin, or to other medicines in the same class (such as aspirin or other NSAIDs). A history of certain allergic reactions, such as asthma attacks or hives, following the use of an NSAID is listed as a contraindication for Indocollyre use.

Q: What should I do if my symptoms get worse while using Indocollyre?

A: If symptoms worsen, official guidance advises that patients should consult a healthcare professional for reassessment. This is particularly important if new signs of infection or severe irritation appear. Official product information cautions that this medicine should not be used alone when an infection is present; separate appropriate treatment is typically needed.

Q: How long after opening should I discard the Indocollyre eye drop bottle?

A: To maintain sterility and effectiveness, regulatory sources specify an expiration period after the bottle is opened. The official product information requires that the bottle must be discarded four weeks after it has been opened for the first time.

Official Storage and Disposal Requirements

Regulatory information defines the following requirements for the proper storage and disposal of Indocollyre (Indometacin) eye drops.

Storage and Handling

Disposal Instructions

Medicines that are no longer needed must be disposed of properly to protect the environment. Regulatory guidance states that the product should not be disposed of via household waste or wastewater. For safe and environmentally responsible disposal, consult a pharmacist for instructions on how to discard unused medicine.